Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Clinical trial NCT05508906 · RECRUITING

Trial details

NCT number: NCT05508906
Sponsor: Olema Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Breast Cancer ER-positive Breast Cancer HER2-negative Breast Cancer Breast Cancer Locally Advanced Breast Cancer

Start date: 2022-08-31
Primary completion: 2027-12-31
Enrollment: 190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.